BioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions

BioLife Solutions, Inc.

today announced its customer Capricor Therapeutics

, a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, announced positive six-month safety and adverse event data from its ongoing DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial evaluating CAP-1002 in patients with advanced heart failure.  The data were highlighted in a poster presentation on November 9 at the 2015 American Heart Association (AHA) Scientific Sessions in Orlando, FL.  BioLife's CryoStor cryopreservation media is an integral component in the manufacturing process of CAP-1002 and is used to freeze and administer these therapeutic cells to heart failure patients.  CAP-1002 is Capricor's lead investigational allogeneic, cardiosphere-derived cell (CDC) therapy. Multi-vessel intracoronary infusion of CAP-1002 in subjects with dilated cardiomyopathy was shown to be safe in this study with no major adverse cardiac events reported at one